RCUS Q2 2019 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+40.0% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$29M-1666.3% margin

Net Income

-$28M-1605.1% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$239M

Total Liabilities

$42M

Stockholders' Equity

$197M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+40.0%
Gross Profit	$2M	$1M	+40.0%
Operating Income	-$29M	-$16M	-83.4%
Net Income	-$28M	-$14M	-107.6%